Comparison
Citicoline vs DHEA
Side-by-side of Citicoline and DHEA. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Citicoline
Citicoline supplement profile: CDP-choline as a phosphatidylcholine precursor, Cognizin dosing 250-2000 mg, cognition trials, stroke recovery evidence.
DHEA
DHEA supplement profile: adrenal androgen precursor, typical 25-50 mg dose, DHEA-S targets, evidence for adrenal insufficiency and vaginal atrophy, side effec.
Effects at a glance
Citicoline
- •Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
- •Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
- •Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
- •ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
- •Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
- •Long uridine half-life (~56 hours) supports once or twice daily dosing
DHEA
- •Adrenal androgen precursor; serum DHEA-S declines progressively after the third decade of life
- •OTC dietary supplement in US under DSHEA 1994; prescription in EU, UK, Canada, Australia
- •FDA approved as Intrarosa (6.5 mg vaginal insert) for postmenopausal dyspareunia in 2016
- •Acts as tissue-specific prohormone converted intracrinologically to testosterone and estrogens
- •Best evidence: adrenal insufficiency replacement and vaginal atrophy; weaker on cognition and longevity
- •WADA banned in competitive sport; banned in NCAA, MLB, NFL, IOC settings
Side-by-side
| Attribute | Citicoline | DHEA |
|---|---|---|
| Category | supplement | hormone |
| Also known as | CDP-choline, cytidine 5'-diphosphocholine, Cognizin | dehydroepiandrosterone, prasterone, Intrarosa |
| Half-life (hr) ↗ | 56 | 12 |
| Typical dose (mg) ↗ | 500 | 25 |
| Dosing frequency | 1 to 2 times daily | daily, typically morning |
| Routes | oral, intravenous | oral, vaginal, topical |
| Onset (hr) | 1 | 1 |
| Peak (hr) | 2 | 1 |
| Molecular weight | 488.32 | 288.42 |
| Molecular formula | C14H26N4O11P2 | C19H28O2 |
| Mechanism | Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production. | Steroid prohormone converted intracrinologically to testosterone and estrogens in target tissues; also exerts direct effects via sigma-1 receptor, GABA-A modulation, and glucocorticoid receptor interaction. |
| Legal status | Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world | OTC supplement in US (DSHEA 1994); prescription in EU, UK, Canada, Australia |
| WADA status | allowed | banned |
| DEA / Rx | OTC supplement (US); Rx in most of the world | OTC supplement in US (not scheduled); Rx in EU, UK, Canada, Australia |
| Pregnancy | Insufficient data for routine use | Contraindicated in pregnancy |
| CAS | 987-78-0 | 53-43-0 |
| PubChem CID | 13804 | 5881 |
| Wikidata | Q411470 | Q411733 |
Safety profile
Citicoline
Common side effects
- mild GI upset
- headache
- restlessness
- occasional insomnia with evening dosing
Contraindications
- concurrent strong anticholinergic therapy
- established cardiovascular disease (TMAO concern, smaller than alpha-GPC)
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors: additive cholinergic effect(minor)
- antimetabolite chemotherapy (5-FU): theoretical cytidine pathway interaction(minor)
DHEA
Common side effects
- acne
- oily skin
- hirsutism (women)
- gynecomastia (men, higher doses)
- irritability
- insomnia
Contraindications
- hormone-sensitive cancer (breast, ovarian, prostate)
- active liver disease
- uncontrolled lipid disorder
- pregnancy and lactation
Interactions
- warfarin: case reports of altered INR; monitor(moderate)
- estrogens (HRT): additive estrogenic effect via conversion; monitor(moderate)
- insulin: may improve insulin sensitivity slightly; monitor glucose(minor)
- anastrozole: may reduce DHEA-derived estrogen; clinical relevance unclear(minor)
Which Should You Take?
Citicoline and DHEA score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.
- → If your priority is focus or working memory, pick Citicoline.
- → If your priority is stroke recovery, pick Citicoline.
- → If your priority is hormonal optimization, pick DHEA.
- → If your priority is healthspan extension, pick DHEA.
Edge case: DHEA is contraindicated in pregnancy; Citicoline is the safer pick if that applies.
Default choice: either is defensible. Citicoline edges out on goal breadth + legal accessibility; DHEA is the right call if your priority sits in the goals listed above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Citicoline and DHEA?
Citicoline and DHEA differ in category (supplement vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Citicoline or DHEA?
Citicoline half-life is 56 hours; DHEA half-life is 12 hours.
Can you stack Citicoline with DHEA?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper